CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System-Reference-Cited by-同舟云学术

CYP2C19 Allele Frequencies in Over 2.2 Million Direct‐to‐Consumer Genetics Research Participants and the Potential Implication for Prescriptions in a Large Health System

Published:2020-07-21 Issue:6 Volume:13 Page:1298-1306
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Ionova Yelena¹,Ashenhurst James²,Zhan Jianan²,Nhan Hoang²,Kosinski Cindy²,Tamraz Bani¹,Chubb Alison²

Affiliation:

1. School of Pharmacy University of California San Francisco California USA

2. 23andMe, Inc. Sunnyvale California USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12830

Reference48 articles.

1. Lias C.H.23andMe Personal Genome Service (PGS) Pharmacogenetic Reports.U.S. Food and Drug Administration Division of Chemistry and Toxicology Devices. (2019). Accessed February 2 2019.

2. National Institute of Health.Cytochrome p450. Genetics Home Reference. (2018). Accessed October 29 2018.

3. Pharmacogenomics and Individualized Drug Therapy

4. PharmGKB summary

5. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accuracy and technical characteristics of CYP2C19 point of care tests: a systematic review;Pharmacogenomics;2024-09-04

2. Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study;Clinical and Translational Science;2024-09

3. CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association;Circulation;2024-08-06

4. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM;Journal of the American Heart Association;2024-08-06

5. Does one size really fit all? The case for personalized antiplatelet therapy in interventional cardiology;Future Cardiology;2024-08-02